Abstract: Objective :To study the prognostic factors for synovial sarcoma. Methods :The expressions of E-cad, MMP-2 and Ki-67 in 72 cases of synovial sarcoma were detected by immunohisto-chemistry. 14 clinicopathological factors influencing prognosis were studied by individual variable and multivariate analyses. Results :1) (-), (+), (++) and (+++) of E-cad were observed in 11 cases (15.28%), 22 cases (30.56%), 22 cases (30.56%) and 17 cases (23.60%) respectively. (-),(+),(++) and (+++) of MMP-2 were observed in 11 cases (15.28%), 18 cases (25.00%), 17 cases (23.60P) and 26 cases (36.12%) respectively. Ki-67 labeling index (LI) was 2.00%~73.00P (28.30%±16.61P). 2) The over-all cumulative survival rate was 86.44% at 1 year, 54.24% at 3 year, 28.81% at 5 year, 16.95% at 7 year and 8.47% at 10 year. 3) Surgical margin, metastasis, histological grade, clinical stage, Ki-67 LI, expression of E-cad and MMP-2 were the prognostic factors by individual variable analysis (P<0.05). 4) A multivariate analysis showed clinical stage, expression of E-cad and MMP-2 were associated with prognosis (χ²=21.00, v=3,P=0.000). Conclusions : Clinical stage, E-cad and MMP-2 are the important prognostic factors for patients with synovial sarcoma.